Daniel Piacquadio, MD
Enriched profileFounder, President and CEO, Therapeutics, Inc. (Therapeutics Clinical Research) · Therapeutics Clinical Research
Daniel Piacquadio is Founder, President and CEO, Therapeutics, Inc. (Therapeutics Clinical Research) at Therapeutics Clinical Research. ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Daniel Piacquadio, M.D., is Founder, President and CEO, Therapeutics, Inc. (Therapeutics Clinical Research). The public record shows 41 publications with 1,657 citations (h-index 18), centered on Alopecia, Tinea, Tinea Pedis. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 2 companies.
- Top research focus: Alopecia
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Study of TDM-180935 in Atopic Dermatitis Patients
Sponsor: Technoderma Medicines Inc.
- Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
Sponsor: Technoderma Medicines Inc.
- A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects
Sponsor: Technoderma Medicines Inc.
Industry payments
Updated 16 Oct 2026
2 companies reported payments to CMS in program years 2023–2025. These are public disclosures, not judgments. The latest:
- Galderma Laboratories, L.P.Program year20251 payment
- PFIZER INC.Program year20241 payment
- PFIZER INC.Program year20232 payments
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Treatment Satisfaction and Acceptability of 20% Aminolevulinic Acid Photodynamic Therapy for the Treatment of Actinic Keratoses of the Face, Scalp, and Upper Extremities.
PubMed
2023 - 25988 Acceptability of 20% aminolevulinic acid photodynamic therapy for treatment of actinic keratoses on the upper extremities in a phase 3, randomized, vehicle-controlled trial
Journal of the American Academy of Dermatology
2021 - A Randomized Trial of Broad Area ALA–PDT for Field Cancerization Mitigation in High-Risk Patients
Journal of Drugs in Dermatology
2020 - A Randomized Trial of Broad Area ALA–PDT for Field Cancerization Mitigation in High-Risk Patients
Journal of Drugs in Dermatology
2020
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/daniel-piacquadio-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- M.D.
University of Pennsylvania
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗ - B.S.
Biomedical Engineering, Rensselaer Polytechnic Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗ - Dermatology residency training
University of California, San Diego
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗
- Fellow
American Academy of Dermatology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania